We use cookies to help provide you with the best possible online experience. By using this site, you agree that we may store and access cookies on your device. You can find out more about how to set your own preferences here.
Accept cookies

Cerbios confirmed by D&B in the top 500 Swiss companies with the lowest Risk Indicator

Lugano / Barbengo, June 12 2013

Cerbios-Pharma SA (from now on Cerbios) is proud to share with you the Dun & Bradstreet newly issued Rating Certificate confirming Cerbios as a company with Risk Indicator of 1 (D&B Risk Indicators 1 mean minimum risk;  4 means, high risk).

Top rating companies are characterized by financial stability and a top or high credit standing (irrespective of the size of their company).

“This external certification, available for our partners and potential partners, is extremely important in order to confirm the robust financial situation and success of the company strategy started several years ago” says Dr. Gabriel Haering, Cerbios’ CEO.

“When starting a new collaboration, being for established products or for new projects as CMO for the development and manufacturing of New Chemical or Biological Entities, it is becoming normal for us to also be audited from the financial point-of-view. “

In fact, what customers want from their suppliers or new potential suppliers are HARD FACTORS like

  1. High quality standard and track records (FDA, PMDA, Swissmedic,…)
  2. Certifications (GMP, Safebridge,….)
  3. Innovative Technologies
  4. Financial stability
  5. Ownership structure and company strategy 

And, on top of it, also the so-called SOFT FACTORS

  1. Reliability
  2. Competence
  3. Communication
  4. Responsiveness
  5. Speed of reaction

The financial stability of a supplier, combined with a long-term strategy, is of great importance because it provides the confidence that the supply of APIs from the qualified source will continue in the coming years without putting in trouble the registration’s holder or the supply of clinical trial material.

The financial risk assessment of a new strategic supplier is an essential part of the supplier qualification phase.

This is already common practice for medium-large pharma companies that are choosing carefully the strategic partner.

We understand that it is more difficult for Biotech or Start-ups where the driving force of the project is the proof-of-concept given from positive clinical trials results. However, this should also become standard for small companies.

Everybody should in fact remember that “Price is what you pay. Value is what you get”.

About Cerbios-Pharma SA

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.

Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
[[ getItemTitle(currentIndex) ]]